Drugs Made In America Acquisition II Corp.
DMIIR
NASDAQ0.09
USD
+0.01
- -
CIK
0002040475
ISIN
KYG2851K1123
CUSIP
G2851K112
Return %
Stock
S&P500
1Y
-46.87
15.98
3Y
-46.87
62.25
5Y
-46.87
67.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Roger Bendelac
- Sector
- Financial Services
- Industry
- Financial - Conglomerates
- Address
- 1 East Broward Boulevard New York NY United States of America 33301
- IPO Date
- Dec 4, 2025
- CIK
- 0002040475
- Website
- dmaacorp.com
- Similar Companies
- Business
- Drugs Made In America Acquisition II Corp. (DMIIR) is a blank check company, or special purpose acquisition company (SPAC), focused on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, with an emphasis on the pharmaceutical industry. Incorporated as a Cayman Islands exempted company, it offers investors ordinary shares and rights, where each right entitles the holder to receive one-tenth of one ordinary share upon consummation of an initial business combination; units (DMIIU) comprising one ordinary share and one right began trading on Nasdaq in September 2025, with separate trading of shares (DMII) and rights (DMIIR) commencing December 3, 2025. The company has no current operations or revenues and targets opportunities to mitigate U.S. medical supply chain risks through on-shoring advanced domestic manufacturing technologies for critical drugs. Founded in 2024 and headquartered at 1 East Broward Boulevard, Suite 700, Fort Lauderdale, Florida, the SPAC completed a $500 million initial public offering of 50,000,000 units at $10.00 per unit on September 26, 2025, underwritten by Cantor Fitzgerald & Co. as sole book-running manager, with a 45-day over-allotment option for up to 7,500,000 additional units. Recent developments include the appointment of independent directors Catherine Do, G. Sridhar Prasad, and Myron W. Shulgan to the board in connection with the IPO, as well as private placement commitments from sponsor Drugs Made In America Acquisition II LLC and Cantor Fitzgerald for 1,200,000 private units. No business combination target has been identified as of December 2025. Led by CEO and Chair Lynn Stockwell, the company operates primarily in the U.S. market through its Nasdaq Global Market listings.